{
  "docId": "019de073-9523-714b-a2b4-ffafcdbd0ef0",
  "docSlug": "bc9bef6f52d4d9603180b6eb6c4f9d10",
  "documentTitle": "SAB Biotherapeutics | Results Presentation Deck | 12 slides",
  "authorId": "sab-biotherapeutics",
  "authorName": "SAB Biotherapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 12,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "appendix_methodology",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Details the study sponsorship, location, participant demographics, dosing, and timeline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9523-714b-a2b4-ffafcdbd0ef0/6",
  "deckHref": "/decks/019de073-9523-714b-a2b4-ffafcdbd0ef0",
  "deckJsonHref": "/decks/019de073-9523-714b-a2b4-ffafcdbd0ef0.json",
  "deckAnchorHref": "/decks/019de073-9523-714b-a2b4-ffafcdbd0ef0#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "list",
      "text": "The trial was sponsored by SAB Biotherapeutics and designed with hVIVO Services Limited. The study was conducted at hVIVO Services Limited screening and quarantine facilities in London, England. (EudraCT reference number 2021-001254-56 and registered with ClinicalTrials.gov number NCT04850898).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f0de3a5-b4f7-4bf3-b19f-7b52c9af5b36",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.42
      },
      "kind": "list",
      "text": "60 Participants were randomized prior to challenge 1:1, double-blinded, to receive SAB-176 or placebo 20-24 hours after influenza challenge. Participants received 25 mg/kg of SAB-176 diluted in normal saline at a concentration of 20 mg/ml or an equivalent volume of normal saline (placebo) in a single IV infusion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6705d3c5-4c18-46af-9f44-9ba23df39a59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.95,
        "x": 0.02,
        "y": 0.28
      },
      "kind": "list",
      "text": "Healthy volunteers aged between 18 and 45 years were enrolled between 23 June and 20 Sept 2020. They were screened per protocol to be nonsmokers, healthy, with a body mass index ≥18 and ≤35, no vaccine received within 30 days of infusion, and a A/California/2009/H1N1 serum hemagglutination inhibition (HAI) antibody titer of ≤1:10 within 90 days prior to enrollment.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "787b0cfe-27ae-4ad1-baaf-ff52412e59b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.95,
        "x": 0.02,
        "y": 0.62
      },
      "kind": "list",
      "text": "A previously utilized Influenza H1N1 A/California/2009-like challenge virus was produced by Meridian Life Sciences under Good Manufacturing Practices (Watson et al., 2015; Leibowitz et al., 2020)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82727d3b-8dd2-4451-9cd4-934a31cdd6ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.52
      },
      "kind": "list",
      "text": "Participants were admitted into the hVIVO facility 2 days prior inoculation and were quarantined for up to 11 days (Day -2 to 8) with Influenza challenge occurring on day 0 and SAB-176/placebo infusion on day 1. Participants were discharged on day 8. Participants returned for 1 outpatient visit on day 28.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa727d1e-1ff5-4eb7-b6f0-4cd1bd9fbda6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.33,
        "x": 0.02,
        "y": 0.11
      },
      "kind": "title",
      "text": "Trial Design and Methods",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3244c80a-66bf-4d20-8ce7-19ab0734f4fc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "82afbbbe-68f8-4081-bcc3-9a48481eaa93",
      "evidence": "list/bullet: Healthy volunteers aged between 18 and 45 years were enrolled between 23 June and 20 Sept 2020.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}